Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders

被引:50
作者
Camilleri, Michael
Bueno, Lionel
de Ponti, Fabrizio
Fioramonti, Jean
Lydiard, R. Bruce
Tack, Jan
机构
[1] Mayo Clin, Coll Med, Rochester, MN 55905 USA
[2] INSERM, F-31073 Toulouse, France
[3] Univ Bologna, I-40126 Bologna, Italy
[4] Univ S Carolina, Charleston, SC USA
[5] Catholic Univ Louvain, B-3000 Louvain, Belgium
关键词
D O I
10.1053/j.gastro.2005.08.062
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Medications are commonly used for the treatment of patients with functional gastrointestinal disorders. The general goal of this report is to review the pharmacokinetics and pharmacology of medications used in functional gastrointestinal disorders. Methods included literature review, consensus evaluation of the evidence for each topic assigned originally to 1 or 2 authors, and broader review at a harmonization session as part of the Rome III process. This report reviews the animal models that have been validated for the study of effects of pharmacologic agents on sensation and motility; the preclinical pharmacology, pharmacokinetics, and toxicology usually required for introduction of novel therapeutic agents; the biomarkers validated for studies of sensation and motility end points with experimental medications in humans; the pharmacogenomics applied to these medications and disorders; and the pharmacology of agents that are applied or have potential for treatment of functional gastrointestinal disorders, including psychopharmacologic agents. Clinician and basic investigators involved in the treatment or investigation of functional gastrointestinal disorders or disease models need to have a comprehensive understanding of a vast range of medications. It is anticipated that the interaction between investigators of basic science, basic and applied pharmacology, and clinical trials will lead to better treatment of these disorders.
引用
收藏
页码:1421 / 1434
页数:14
相关论文
共 121 条
[71]   Tachykinin NK2 receptor antagonists for the treatment of irritable bowel syndrome [J].
Lecci, A ;
Capriati, A ;
Maggi, CA .
BRITISH JOURNAL OF PHARMACOLOGY, 2004, 141 (08) :1249-1263
[72]   Current concepts: Chronic constipation [J].
Lembo, A ;
Camilleri, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (14) :1360-1368
[73]   Irritable bowel syndrome patients show altered sensitivity to exogenous opioids [J].
Lembo, T ;
Naliboff, BD ;
Matin, K ;
Munakata, J ;
Parker, RA ;
Gracely, RH ;
Mayer, EA .
PAIN, 2000, 87 (02) :137-147
[74]   Meta-analysis: the treatment of irritable bowel syndrome [J].
Lesbros-Pantoflickova, D ;
Michetti, P ;
Fried, M ;
Beglinger, C ;
Blum, AL .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 20 (11-12) :1253-1269
[75]   Intracolonic injection of glycerol: A model for abdominal pain in irritable bowel syndrome? [J].
Louvel, D ;
Delvaux, M ;
Staumont, G ;
Camman, F ;
Fioramonti, J ;
Bueno, L ;
Frexinos, J .
GASTROENTEROLOGY, 1996, 110 (02) :351-361
[76]  
Lydiayd RB, 2001, J CLIN PSYCHIAT, V62, P38
[77]  
Maganti K, 2003, AM J GASTROENTEROL, V98, P259
[78]  
Malcolm A, 2000, ALIMENT PHARM THERAP, V14, P783
[79]   Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? [J].
Masand, PS ;
Gupta, S ;
Schwartz, TL ;
Kaplan, D ;
Virk, S ;
Hameed, A ;
Lockwood, K .
PSYCHOSOMATICS, 2002, 43 (06) :451-455
[80]  
McCallum RW, 1999, ALIMENT PHARM THERAP, V13, P77